Resource for journalists around the world on COVID-19 vaccines

covidvaccinehub.org (https://covidvaccinehub.org/)
If you’re a fact checker or a journalist, we’re here to help you find the information and experts you need for your story.

SYDNEY, Nov. 22, 2021 /PRNewswire/ — The COVID-19 Vaccine Media Hub (https://covidvaccinehub.org/) is a dedicated global resource for journalists and fact checkers wanting access to evidence-based information on COVID-19 vaccines with material available in multiple languages.

The Hub collates information on COVID-19 vaccines from trustworthy sources, including explainers, summaries of the latest research, expert comments, and online media briefings.

The project is a combined effort, with contributions from Science Media Centres and other not-for-profit organisations in Australia, the UK, Germany, Taiwan, Africa, Canada, the US, Spain and New Zealand. A full list of contributing organisations is available on the hub.

Journalists can also use the hub to sign up to a regular alert and use the network to ask questions about vaccines in different countries or to ask for help with a story.

This collaboration was made possible through a grant from the Google News Initiative. All organisations involved are independent and are focused on helping journalists and factcheckers find accurate information and credible experts on COVID-19 vaccines.

For further information, please visit (https://covidvaccinehub.org/) or contact the Australian Science. Media Centre via email info@smc.org.au or +61 8 7120 8666.

ABOUT US: The Australian Science Media Centre is an independent, not-for-profit Centre working to enhance the media’s coverage of science, for the benefit of all. We provide the evidence and experts when science hits the headlines and administer the breaking science news portal for our region – scimex.org. The Centre is part of a global network of science media centres.

Enernet Global acquires KPS Power Africa

Distributed energy service company accelerates presence in Africa with acquisition of African subsidiary of KPS Australia

NEW YORK, Nov. 22, 2021 (GLOBE NEWSWIRE) — Enernet Global Inc. (“Enernet”), a distributed energy service company whose mission is to decarbonise the world’s supply chains, acquired KPS Power Africa (“KPSPA”) to accelerate presence in African mining.

Enernet’s global footprint enables it to provide tailored energy solutions for mining, commercial, industrial, remote community and utility customers across its operations in Australia, the Philippines, the Caribbean and Sub-Saharan Africa. KPSPA finances, builds, owns and operates hybrid power plants for the mining sector in Africa. The transaction provides Enernet with a portfolio of projects and expert team to rapidly scale the business.

“The combination of KPS Power Africa’s deep roots in mining and power in Africa combined with Enernet’s world-leading expertise on renewable hybrid plants and competitive capital enables us to bring a unique solution to mines across Africa,” said Paul Matthews, Enernet and KPSPA’s CEO. “Mines are under increasing pressure to reduce scope 1, 2 and 3 emissions and their CEOs must report to investors and the market on their ambitions to reduce CO2. Together, we finance, build and operate cheaper, cleaner and more reliable power solutions for customers across Sub-Saharan Africa.”

“The acquisition of KPSPA by Enernet Global is a great strategic move which allows both companies to advance hybrid power generation within mining in Africa. KPSPA has increased its exposure to the renewable energy market and Enernet Global its presence in the African mining industry, which is ideally positioned for renewable hybrid system,” said Ben Zikmundovsky, KPSPA’s General Manager.

Enernet and KPSPA deploy distributed on- and off-grid generation projects that integrate renewable energy, battery storage, cogeneration and existing thermal or grid supply. System design and operational optimization are underpinned by Enernet’s patented technology platform.

Selling energy and services through power purchase agreements, systems are delivered at no capital cost to customers and tailored to their specific energy needs. This lowers costs, adds energy resilience and independence, and dramatically reduces emissions mines in Africa.

About Enernet Global Inc (“Enernet”)
Enernet is a distributed energy service provider that finances, builds, owns and operates microgrids and drives the adoption of renewable energy, battery storage and energy efficiency solutions that displace CO2 emissions. Built on the company’s proprietary software platform, Enernet’s Energy-as-a-Service offering benefits on- and off-grid customers by providing less expensive, more resilient power solutions at no capital outlay for customers.

Enernet has operations in Australia, the Philippines, the Caribbean and Sub-Saharan Africa, where it focuses on power solutions for sectors that include island development, mining, commercial and industrial, remote communities, agriculture, utilities and hospitality.

About KPS Power Africa (“KPSPA”)
KPS Power Africa specialises in designing, building, owning and operating power stations for African mining operations. As a leading contract power supplier to the mining sector, KPSPA provides independent power generation services with the benefit of over 30 years’ experience in African mining.

Servicing all of Africa, KPSPA’s purpose-built power generation systems include design, construction, operation and maintenance, reducing customers’ capital and maintenance requirements. Capabilities and expertise cover multiple technologies and deliver benchmark reliability and fuel efficiency for our customers’ mining operations.

Media contact:
Paul Matthews
Enernet Global Inc.
Office: +1 541 292 6422
Email: pmatthews@enernetglobal.com

Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor

Xencor receives rights to additional equity in Zenas as upfront payment and is eligible for up to $480 million in potential milestone payments and royalties on net sales of commercialized products

Obexelimab is a novel bifunctional antibody with first-in-class potential to treat autoimmune diseases

MONROVIA, Calif., HONG KONG and BOSTON, Nov. 21, 2021 (GLOBE NEWSWIRE) — Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and Zenas BioPharma (“Zenas”), a global biopharmaceutical company based in the USA and China committed to the development and delivery of immune-based therapies, today announced that Zenas has acquired from Xencor exclusive worldwide rights to develop, manufacture and commercialize the investigational antibody obexelimab.

Obexelimab is a potential first-in-class bifunctional antibody that targets CD19 with its variable domain and uses Xencor’s XmAb® Immune Inhibitor Fc Domain to target FcγRIIb, a receptor that inhibits the function of B-cells, which are important components in the immune system. Xencor demonstrated through early-stage clinical studies that obexelimab effectively inhibits B-cell function without depleting the cells and generates an encouraging treatment effect in patients with multiple autoimmune diseases.

“Zenas is advancing a broad pipeline of differentiated drug candidates that are intended to bring best-in-class innovation to patients with underserved medical needs,” said Hua Mu, Ph.D., MD, president and chief executive officer at Zenas. “Today, we are pleased to add obexelimab to our portfolio, and based on its clinical profile, we believe it is positioned as a first-in-class candidate with the potential to treat numerous autoimmune diseases.”

“Obexelimab’s highly potent and broad blockade of B-cell activation—without depleting B cells—differentiates it from other B-cell targeting therapies, and it has demonstrated disease-modifying activity in settings where B-cell inhibition is a proven strategy,” said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. “In Zenas BioPharma, we have found a partner committed to broadly and aggressively developing therapeutics like obexelimab for patients with autoimmune diseases, enabling Xencor’s continued focus on the growing opportunities provided by our XmAb bispecific antibody and cytokine pipeline.”

Under the terms of the new agreement, Zenas will issue to Xencor a warrant giving Xencor the right to acquire additional Zenas equity, such that Xencor’s total equity in Zenas would be 15% of its fully diluted capitalization following the closing of Zenas’ next round of equity financing, subject to certain requirements. Xencor previously received equity in Zenas under a separate license agreement. Xencor is also eligible to receive up to $480 million based on the achievement of certain clinical development, regulatory and commercialization milestones and is eligible to receive tiered, mid-single digit to mid-teen percent royalties upon commercialization of obexelimab, dependent on geography. Zenas will have sole responsibility for advancing the research, development, regulatory and commercial activities of obexelimab worldwide.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 22 candidates engineered with Xencor’s XmAb® technology are in clinical development internally and with partners. Xencor’s XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company based in the USA and China committed to becoming a leader in the development and delivery of immune-based therapies for patients in the US, China and around the world. Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

Xencor Forward-Looking Statements

Certain statements contained in this press release may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include statements that are not purely statements of historical fact, and can generally be identified by our use of words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” and similar terms, or by express or implied discussions relating to the development of obexelimab as a potential treatment for patients with autoimmune diseases; the commercial potential of obexelimab; the safety, tolerability, efficacy and pharmacokinetics of obexelimab; the quotations from Xencor’s president and chief executive officer; and other statements that are not purely statements of historical fact. Such statements are made on the basis of the current beliefs, expectations, and assumptions of the management of Xencor and are subject to significant known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs that are safe and effective for use as human therapeutics and other risks described in Xencor’s public securities filings. For a discussion of these and other factors, please refer to Xencor’s annual report on Form 10-K for the year ended December 31, 2020 as well as Xencor’s subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended to date. All forward-looking statements are qualified in their entirety by this cautionary statement and Xencor undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

Contacts

Xencor Investor Contact:
Charles Liles
cliles@xencor.com

Xencor Media Contact:
Jason I. Spark
Canale Communications
619-849-6005
jason@canalecomm.com

Zenas Investor Contact:
IR@zenasbio.com

Zenas Media Contact:
Lauren Bartlett
lauren.bartlett@zenasbio.com

Zenas BioPharma Adquire Direitos Mundiais Exclusivos do Obexelimab da Xencor

Xencor recebe direitos sobre ações adicionais da Zenas como pagamento antecipado e é elegível para até US$ 480 milhões em pagamentos de marcos potenciais e royalties sobre vendas líquidas de produtos comercializados

O obexelimab é um novo anticorpo biespecífico com potencial de primeira classe para tratar doenças autoimunes

MONROVIA, Califórnia, HONG KONG e BOSTON, Nov. 21, 2021 (GLOBE NEWSWIRE) — A Xencor, Inc. (NASDAQ: XNCR), uma empresa biofarmacêutica de estágio clínico que desenvolve citocinas e anticorpos monoclonais projetados para o tratamento de câncer e doenças autoimunes, e a Zenas BioPharma (“Zenas”), uma empresa biofarmacêutica global com sede nos EUA e na China comprometida com o desenvolvimento e oferta de terapias imunológicas, anunciou hoje que Zenas adquiriu da Xencor direitos exclusivos em todo o mundo para desenvolvimento, fabricação e comercialização do anticorpo investigacional obexelimab.

O obexelimab é um potencial anticorpo bifuncional de primeira classe que tem como alvo o CD19 com seu domínio variável e que usa o domínio Fc do inibidor imunológico XmAb ® da Xencor para ter como alvo o FcγRIIb, um receptor que inibe a função das células B, os componentes importantes no sistema imunológico. A Xencor comprovou, através de estudos clínicos em fase inicial, que o obexelimab inibe eficazmente a função das células B sem reduzir as células, e gera um efeito encorajador no tratamento de doentes com múltiplas doenças autoimunes.

“A Zenas está desenvolvendo um amplo pipeline de candidatos a medicamentos diferenciados que se destinam a aprimorar a inovação da categoria para pacientes com necessidades médicas mal atendidas”, disse Hua Mu, Ph.D., MD, presidente e diretor executivo da Zenas. “É com prazer que incluímos o obexelimab no nosso portfólio e, com base no seu perfil clínico, acreditamos que ele está bem-posicionado como candidato de primeira classe com potencial para tratamento de inúmeras doenças autoimunes.”

“O bloqueio altamente potente e amplo da ativação das células B do Obexelimab – sem reduzir as células B – o diferencia das outras terapias direcionadas às células B, além de ter comprovado a atividade modificadora da doença em ambientes onde a inibição das células B é uma estratégia comprovada”, disse Bassil Dahiyat, Ph.D., presidente e diretor executivo da Xencor. “A Zenas BioPharma encontrou um parceiro comprometido com o desenvolvimento amplo e agressivo de terapêuticas como obexelimab para pacientes com doenças autoimunes, permitindo o foco contínuo da Xencor nas oportunidades crescentes fornecidas pelo nosso pipeline de citocinas e de anticorpo biespecífico XmAb.”

Sob os termos do novo contrato, a Zenas emitirá para a Xencor uma autorização para a Xencor adquirir capital adicional da Zenas, de modo que o capital total da Xencor na Zenas seria de 15% da sua capitalização totalmente diluída após o fechamento da próxima rodada de financiamento de capital da Zenas, sujeito a certos requisitos. A Xencor recebeu anteriormente ações da Zenas sob um contrato de licença separado. A Xencor também é elegível para receber até US$ 480 milhões com base na realização de certos marcos de desenvolvimento clínico, regulatório e de comercialização, e também é elegível para receber royalties escalonados, de um dígito a dois dígitos de percentual após a comercialização do obexelimab, de acordo com a área geográfica. A Zenas será a única responsável pelo avanço das atividades de pesquisa, desenvolvimento, regulatórias e comerciais do obexelimab em todo o mundo.

Sobre a Xencor, Inc.

O Xencor é uma empresa biofarmacêutica de estágio clínico que desenvolve citocinas e anticorpos monoclonais manipulados para o tratamento de câncer e de doenças autoimunes. No momento, 22 candidatos projetados com a tecnologia XmAb® da Xencor estão em desenvolvimento clínico interno e com parceiros. A tecnologia de engenharia de anticorpos XmAb da Xencor permite pequenas mudanças na estrutura das proteínas, resultando em novos mecanismos de ação terapêutica. Para mais informação, visite www.xencor.com.

Sobre a Zenas BioPharma

A Zenas BioPharma é uma empresa biofarmacêutica mundial com sedes nos EUA e na China, comprometida em se tornar líder global no desenvolvimento e oferta de terapias imunológicas para pacientes nos EUA, China e em todo o mundo. A Zenas está avançando rapidamente um vasto pipeline de terapêuticas inovadoras que continua a crescer por meio da nossa estratégia de desenvolvimento de negócios de sucesso. Nossa experiente equipe de liderança e rede de parceiros de negócios impulsionam a excelência operacional para oferecer terapias potencialmente transformadoras para melhorar a vida das pessoas que enfrentam doenças autoimunes e raras. Para mais informação sobre a Zenas BioPharma, visite www.zenasbio.com e siga-nos no Twitter em @ZenasBioPharma e LinkedIn.

Declarações de Previsão da Xencor

Certas declarações contidas neste comunicado de imprensa podem ser consideradas “declarações de previsão” do termo de títulos aplicáveis, As declarações de previsão incluem declarações que não são puramente declarações de fatos históricos e geralmente podem ser identificadas pelas palavras “potencial”, “pode”, “irá”, “planeja”, “deve”, “poderia”, “iria”, “espera”, “antecipa”, “procura”, futuro”, “acredita”, “comprometido”, “investigacional” e termos semelhantes, ou por discussões expressas ou implícitas relacionadas ao desenvolvimento do obexelimab como tratamento potencial de pacientes com doenças autoimunes; o potencial comercial do obexelimab; a segurança, tolerabilidade, eficácia e farmacocinética do obexelimab; as citações do presidente e do diretor executivo da Xencor; e outras declarações que não sejam puramente declarações de fatos históricos. Essas declarações são feitas com base nas convicções, expectativas e suposições da administração da Xencor no momento, e estão sujeitas a riscos, incertezas e outros fatores significativos conhecidos e desconhecidos que podem fazer com que os resultados, desempenho ou realizações e ocasião dos eventos sejam substancialmente diferentes dos implícitos em tais declarações e, portanto, essas declarações não devem ser interpretadas como garantias de desempenho ou resultados futuros. Tais riscos incluem, sem limitação, os riscos associados ao processo de descoberta, desenvolvimento, fabricação e comercialização de medicamentos seguros e eficazes para uso como terapêutica humana, e outros riscos descritos nos registros de títulos públicos da Xencor. Para uma discussão sobre esses e outros fatores, consulte o relatório anual da Xencor no Formulário 10-K do exercício encerrado em 31 de dezembro de 2020, bem como os registros subsequentes da Xencor na SEC dos EUA. O investidor não deve depositar confiança indevida nas declarações de previsão, que são válidas somente até a presente data. Este aviso está em conformidade com as disposições de porto seguro da Private Securities Litigation Reform Act of 1995, alterada até a presente data. Todas as declarações de previsão são totalmente qualificadas por esta declaração de alerta e, nem a MannKind, nem a Biomm, assumem nenhuma obrigação de atualizar ou revisar quaisquer declarações de previsão para revelar eventos ou circunstâncias após a data deste comunicado de imprensa.

Contato

Contato para Investidor da Xencor:
Charles Liles
cliles@xencor.com

Contato para Mídia da Xencor:
Jason I. Spark
Canale Communications
619-849-6005
jason@canalecomm.com

Contato para Investidor da Zenas:
IR@zenasbio.com

Contato para Mídia da Zenas:
Lauren Bartlett
lauren.bartlett@zenasbio.com

Zenas BioPharma acquiert des droits mondiaux exclusifs sur l’Obexelimab auprès de Xencor

Xencor reçoit des droits sur des capitaux propres supplémentaires dans Zenas en tant que paiement initial et est éligible à un maximum de 480 millions de dollars en paiements échelonnés potentiels et redevances sur le chiffre d’affaires net des produits commercialisés

L’Obexelimab est un nouvel anticorps bispécifique avec un potentiel de premier ordre pour traiter les maladies auto-immunes

MONROVIA, Californie., HONG KONG et BOSTON, 22 nov. 2021 (GLOBE NEWSWIRE) —  Xencor, Inc. (NASDAQ: XNCR), une société biopharmaceutique en phase clinique qui développe des anticorps monoclonaux et des cytokines pour le traitement du cancer et des maladies auto-immunes, et Zenas BioPharma (« Zenas »), une société biopharmaceutique mondiale basée aux États-Unis et en Chine engagée dans le développement et l’administration de thérapies immunitaires, ont annoncé aujourd’hui que Zenas avait acquis les droits exclusifs mondiaux de développement, de fabrication et de commercialisation de l’anticorps expérimental obexelimab.

L’Obexelimab est un nouvel anticorps bifonctionnel potentiel qui cible le CD19 avec son domaine variable et utilise le domaine Fc de l’inhibiteur immunitaire XmAb®  de Xencor pour cibler le FcyRIIB, un récepteur qui inhibe la fonction des cellules B, qui sont des composants importants du système immunitaire. Xencor a démontré par le biais d’études cliniques à un stade précoce que l’obexelimab inhibe efficacement la fonction des cellules B sans épuiser les cellules et génère un effet de traitement encourageant chez les patients atteints de multiples maladies auto-immunes.

« Zenas fait progresser un large éventail de médicaments candidats différenciés qui visent à apporter la meilleure innovation de sa catégorie aux patients ayant des besoins médicaux non satisfaits », a déclaré Hua Mu, Ph.D., MD, président-directeur général de Zenas. « Aujourd’hui, nous sommes ravis d’ajouter l’obexelimab à notre portefeuille, et en nous basant sur son profil clinique, nous pensons qu’il s’agit d’un candidat de première classe ayant le potentiel de traiter de nombreuses maladies auto-immunes. »

« Le blocage très puissant et étendu de l’activation des cellules B d’Obexelimab, sans épuiser les cellules B, le distingue des autres thérapies ciblant les cellules B, et il a démontré une activité modifiante de la maladie dans les environnements où l’inhibition des cellules B est une stratégie éprouvée », a déclaré Bassil Dahiyat, Ph.D., président-directeur général de Xencor. « Nous avons trouvé en Zenas BioPharma un partenaire engagé dans le développement large et agressif de traitements tels que l’obexelimab pour les patients atteints de maladies auto-immunes, permettant à Xencor de continuer à se concentrer sur les opportunités croissantes offertes par notre pipeline d’anticorps bispécifique XmAb et de cytokines. »

En vertu des termes du nouvel accord, Zenas émettra à Xencor un bon de souscription donnant à Xencor le droit d’acquérir des capitaux propres Zenas supplémentaires, de sorte que les capitaux propres totaux de Xencor dans Zenas représenteraient 15 % de sa capitalisation entièrement diluée après la clôture du prochain cycle de financement des capitaux propres de Zenas, sous réserve de certaines exigences. Xencor avait précédemment reçu des capitaux propres dans Zenas dans le cadre d’un accord de licence séparé. Xencor pourrait également recevoir jusqu’à 480 millions de dollars en se basant sur la réalisation de certaines étapes de développement clinique, de réglementation et de commercialisation et pourrait recevoir des redevances échelonnées à un chiffre moyen à un pourcentage moyen lors de la commercialisation de l’obexelimab, en fonction de la géographie. Zenas aura la seule responsabilité de faire progresser les activités de recherche, de développement, réglementaires et commerciales d’obexelimab dans le monde entier.

À propos de Xencor, Inc.

Xencor est une société biopharmaceutique en phase clinique qui développe des anticorps monoclonaux et des cytokines conçus pour le traitement du cancer et des maladies auto-immunes. Actuellement, 22 candidats conçus avec la technologie XmAb ®   de Xencor sont en cours de développement clinique en interne et avec des partenaires. La technologie d’ingénierie des anticorps XmAb de Xencor permet de petits changements dans la structure des protéines, entraînant de nouveaux mécanismes d’action thérapeutique. Pour plus d’informations, consultez notre site www.xencor.com.

À propos de Zenas BioPharma

Zenas BioPharma est une société biopharmaceutique mondiale basée en Chine et aux États-Unis déterminée à devenir un leader dans le développement et la fourniture de traitements immunitaires pour les patients aux États-Unis, en Chine et dans le monde entier. Zenas fait rapidement progresser un vaste pipeline de traitements innovants qui continue de s’accroître grâce à notre stratégie de développement commercial fructueuse. Notre équipe de direction expérimentée et notre réseau de partenaires commerciaux stimulent l’excellence opérationnelle pour apporter des thérapies potentiellement transformatrices afin d’améliorer la vie des personnes confrontées à des maladies rares et auto-immunes. Pour tout complément d’information sur Zenas BioPharma, veuillez consulter le sitewww.zenasbio.com et nous suivre sur Twitter à l’adresse @ZenasBioPharma et LinkedIn.

Énoncés prospectifs de Xencor

Certaines déclarations du présent communiqué de presse constituent des « énoncés prospectifs » au sens des lois en vigueur sur les valeurs mobilières. Les énoncés prospectifs incluent des énoncés qui ne sont pas purement des énoncés de faits historiques, et peuvent généralement être identifiés par l’utilisation de mots tels que « potentiel », « peut », « fera », « prévoir », « peut-être », « pourrai », « s’attendre à », « anticiper », « chercher », « être impatient de », « croire », « être engagé », « expérimental » et des termes similaires, soit par des discussions expresses ou implicites relatives au développement de l’obexelimab en tant que traitement potentiel pour les patients atteints de maladies auto-immunes ; le potentiel commercial de l’obexelimab ; la sécurité, la tolérabilité, l’efficacité et la pharmacocinétique de l’obexelimab ; les citations du président-directeur général de Xencor ; et d’autres déclarations qui ne sont pas de simples déclarations de faits historiques. Ces énoncés sont formulés sur la base des convictions, attentes et hypothèses actuelles de la direction de Xencor et sont assujettis à des risques connus et inconnus, incertitudes et autres facteurs importants, susceptibles d’entraîner des résultats, des performances ou des réalisations réels et un calendrier d’événements sensiblement différent de ceux sous-entendus par ces énoncés, et par conséquent, ces énoncés ne doivent pas être lus comme des garanties de performances ou de résultats futurs. Ces risques incluent, sans s’y limiter, les risques associés au processus de découverte, de développement, de fabrication et de commercialisation de médicaments sûrs et efficaces pour une utilisation en tant que traitements humains et d’autres risques décrits dans les dépôts de titres publics de Xencor. Pour une discussion sur ces facteurs et d’autres, veuillez consulter le rapport annuel de Xencor sur le formulaire 10-K pour l’exercice clos le 31 décembre 2020, ainsi que les documents déposés ultérieurement par Xencor auprès de la Securities and Exchange Commission. Nous vous prions de ne pas vous fier indûment à ces énoncés prospectifs, qui ne sont valables qu’à la date des présentes. Cette mise en garde est faite en vertu des dispositions relatives aux règles d’exonération de la loi américaine intitulée Private Securities Litigation Reform Act de 1995, telle qu’amendée à ce jour. Tous les énoncés prospectifs sont qualifiés dans leur intégralité par la présente mise en garde et Xencor décline toute obligation de réviser ou de mettre à jour le présent communiqué de presse afin de refléter des événements ou des circonstances postérieurs à la date des présentes, sauf si la loi l’exige.

Contacts

Contact investisseurs chez Xencor :
Charles Liles
cliles@xencor.com

Contact médias chez Xencor :
Jason I. Spark
Canale Communications
619-849-6005
jason@canalecomm.com

Contact investisseurs chez Zenas :
IR@zenasbio.com

Contact médias chez Zenas :
Lauren Bartlett
lauren.bartlett@zenasbio.com

Young Eritrean Professional Women: Ensuring Equality Through Equal Participation at Work

National development depends on effective utilization of the skills and knowledge and active participation of an entire population. To ensure women’s participation in all walks of life and bring about meaningful national development Eritrea has succeeded in eliminating any form of discrimination, violence and harmful practices against women. It reviewed the laws and regulations inherited from colonization to thwart discrimination against women. It has made transformation in gender relations which has been made possible through advances in education, health and other social services.

Women’s enrollment in schools, including colleges, at par with their men counterparts is just one example of the government’s commitment to ensuring social justice through women’s empowerment. Eritrean women enjoy all the rights stipulated in the international labor conventions. They are guaranteed equality of employment opportunities and equal pay as men for the same job.

Women have been key players in Eritrea’s history. Their invaluable participation in the long struggle for independence and the ongoing process of nation building have been recorded on the pages of history. Without the active participation of women, Eritrea’s independence would not have been realized. In fact, the struggle for women’s equality was waged as part of the struggle for independence.

Inspired by this powerful legacy, some young educated Eritrean women took an initiative to establish an association committed to the realization of gender equality and to increase awareness of gender issues in the society. The group of young professional women was established in 2019 by young women with college education who were assigned to different government offices. In its three years of existence, the association has earned a reputation as an outspoken, courageous, and creative movement pushing for change.

Ms. Miriam Yossief, a member of the management team of the association who works at the Anseba region’s Ministry of Education office, said the idea to establish the association emanated from the conviction “to contribute something positive to our society from what we have learned.” The young women professionals, aged 22 to 30, represent a number of professions and come from 31 government institutions. The fact that they all went to Sawa to complete their high school education and do their national service and then went to college before they were assigned to ministries to work provided them with a commonality of a lived experience and perspective on how to contribute in the struggle for gender equality. They are utilizing creative strategies to effect the change they want to see in the country, and through their collective strength they are playing a role in strengthening the National Union of Eritrean Women (NUEW).

The association has organized many forums and seminars on law and women, women’s organization, gender mainstreaming in relation to national gender policy, young women empowerment in education, the role of women in nation building and national identity, migration and its implications for women . The young professional s have conducted campaigns in middle and secondary schools, Sawa, colleges, villages, and government offices. In addition to their regular annual trip to Sawa and colleges, they have visited many villages and had discussions with women in those locations. They have so far visited and had meetings with the inhabitants of Adi-Hawsha, Weki, Serejeka, Zagir, Deqiseb, Tsaeda-krstian, Afdeyu, Hnbrti, Adi-Guadad and Adi-Nifas to discuss matters pertaining to gender issues. Through seminars and discussion forums they provide venues for sharing ideas with students, workers, mothers and members of the Eritrean Defense Forces. Although the youth are mainly targeted by the association, mothers are also included in the campaigns.

The young group of Eritrean women professionals is operating under the auspices of the NUEW, which was established in 1979 with the support of the Eritrean People’s Liberation Front. In its present form, NUEW is an autonomous non-governmental organization dedicated to improving the status of Eritrean women in the society and increase their contribution in the country. The organization’s mission is to ensure that all Eritrean women confidently stand for their rights and equally participate in the political, economic, social and cultural spheres of the country and share the benefits. The constitution of NUEW has encouraged women to protect their rights by organizing themselves, and the young group of Eritrean women professionals is working towards the full realization of the objectives and mission of the organization.

The contribution of the association of the young women professionals to empower and mobilize women for nation building is immensely needed. The group of young women professionals are enthusiastic and confident to take the struggle for their complete emancipation forward and create a society where men and women live as equals in harmony. The association’s objectives include empowering women, ensuring the sustainability of the principles of NUEW, fostering cooperation among group members and participating in national campaigns. Through its stated objectives and practical works, the association of young women professionals has demonstrated its willingness to continue the journey Eritrean women started during the revolution under the slogan “Equality through equal participation at work.”

Education is one the most powerful weapons for girl’s development. Educated women are empowered women. Investment in women’s education is essential for poverty reduction, and socio-economic growth. When girls go to school, they develop into women who have more say over their lives and have an increased sense of their own worth.

Dramatic changes in the status of Eritrean women have been made thanks to the government’s gender conscious policies, and the association of the young women professionals is working with numerous stakeholders to eliminate discrimination totally and create ample opportunities for women to thrive.

Source: Ministry of Information Eritrea

Don’t Merely Dream- Create!

To do and to think are two different things. Your willingness to do what you need to do, pay the price needed, go the distance required, and make every possible sacrifice demanded is the measurement of how badly you really want to achieve your goal. If you believe you are destined to be successful, and you hold on to this belief no matter what happens, then there is nothing that can stop you from becoming that great success. Eng. Abiel, Eng. Fanuel, Eng. Meron and Eng. Siem are our invited guests for today’s Q&A column. These engineers are typical examples of those who are willing and working to become tomorrow’s great success. These engineers were able create the Tigrigna Text to Speech Engine (TTSE). The interview follows:

• First, I thank you for agreeing to this interview. So tell us something about yourselves.

My name is Meron Mehreteab. I studied my secondary education in Asmara and headed to Sawa with the 29th round. I scored 3.4 on my matriculation exam and joined the Computer Engineering department in Mai-nefhi College of Engineering and Technology. I completed my college education with distinction.

My name is Abiel Amanuel. I studied at Barka Secondary School in Asmara and went to Sawa with the 29th round to complete my high school education and scored 3.6 in the matriculation exam. The same as my friends, I joined the department of Computer Engineering and received my first Degree from Mai-nefhi College of Engineering and Technology.

My name is Fanuel Teklemariam. I studied at Asmara-Hafeshawi Secondary School and headed to Sawa with the 29th round. I got 3.4 in my matriculation exam and joined the department of computer engineering and finished my five year studies there.

My name is Siem Haile. I studied at St. Mary Secondary School and went to Sawa with the 29th round to complete my national service and secondary education. I scored 3.8 in my matriculation exam and joined the College of Engineering and Technology.

• Was there any particular reason for you to study Computer Engineering?

Siem: Definitely! With the growing technological advancement, I always imagined being flexible in the work I perform. Therefore, I considered studying Computer Science as a way to achieve my goals, and I believed it could rhyme with what I always wanted.

Meron: There was an ICT teacher in my neighborhood who used to show me some computer applications back in my high school days. That grew up with me, and I always thought of joining the department of computer engineering. Hence from all the options at the College of Engineering and Technology, I had to choose only one and that was computer engineering. Nowadays, computer engineering is becoming influential as technology is trending and that’s why I chose it as it is more applicable.

Abiel: When I was in high school, I started to realize that almost everything was being computerized and came to be fond of it when I went to Sawa. A demonstration was given by my teachers which left an impression on me. Not only that, but my parents were also very supportive when I told them that I was going to study computer engineering. With their support and inner ambition, I finally joined the department.

Fanuel: My uncle, my cousin and my two siblings are computer engineers. Having such influences around me was a simple reason for my inclination towards computer engineering. Especially my sister played the biggest role for me to join that department.

• Tell us something about your senior paper

Meron: In fourth year, we took an introductory course on Artificial Intelligence (AI) and we were more motivated when we started fifth year. At the beginning, our plan was to create something related to robotics in connection to AI, particularly targeting the disabled, mainly those who can’t move their body or body parts. However, we didn’t go through with it because the finance and material required for the project was beyond our capacity. Therefore, we started brainstorming ideas on what we could do within our boundaries and cost-effective if possible. We then chose text to speech as a possible application to develop because it could somehow meet our criteria. To tell you something about the project, using AI, introducing Tigrigna to the rest of the world and allowing Eritreans to benefit from it was our aim. The project is mainly an AI which can imitate Tigrigna speech. We collected enough data and the sentences were prepared with their corresponding speech. Simply, our project was implemented in a way that raw text and audio data is provided to the end to end machine learning algorithm Tacotron proposed by Google (https://arxiv.org/pdf/1703.10135. pdf) in order to extract complex phoneme relationships among the different Tigrigna characters and then these extracted patterns can be used to synthesize speech of any given words.

• Is your project targeted to a specific section of the society?

Abiel: It is made to assist all members of the society equally. However, to arrange them in accord to the importance of the project to the users, those who cannot see or with sight problems are our priority targets. Those who cannot see, cannot read and to fill in what they are missing; this project can be helpful. Our second targets are Eritreans living abroad. These Eritreans, especially those having problems mastering the Tigrinya language, can be beneficiaries too. Our third target was the airport. This machine can assist travelers by notifying them their arrival and departure time in Tigrigna. All in all, this project is intended to help everyone in any way posible.

• Did you encounter challenges while developing the project?

Our primary challenge was the fact that we were unfamiliar with such kind of technology because we only took one introductory course on AI and another on data mining (which we took when we were already halfway with our project) which was not enough to develop something out of it. Financial constraint was also another bottleneck for our project. As students we could only meet the expenses for the project to a limited extent. We knew from the beginning that we would be short of cash but it would be unfair to stop such a project because of money. The third challenge is the language. Tigrigna is a less sourced language and you cannot find the data for it easily. Another thing is we couldn’t record and we were left with no choice but to use audio books. However, we couldn’t find the editable written form of these audio books and we had to script it. Speech was crucial and we depended on it. Therefore, while training the artificial intelligence machine learning, high computational power was needed and this was challenging. In general, text to speech is more cost-effective to do as an enterprise, but we managed to tackle those impediments.

• Well, what are you planning to do in the future?

This project is quite big to be held only by students like us. Within that limited period and the data we were provided with (using 11,000 Tigrigna words) we were able to reach this stage. It is not deployable yet but at least we tried to demonstrate that it can be something big with time and financial support. Therefore, in the near future, we will try to make it deployable so that everyone could get the best out of it. To do so, we will need to collect more sentences and we are in the process of publishing it.

• Any final remarks?

Our parents who gave us the motivation and financial support were the backbones for the success of our project, so we thank them. We also want to extend our gratitude to Dr. Yemane for his expertise advice. Writer Eden, studio-man Siem, Isaiah who was the narrator, our friends especially Henok Araia, Nahom Hagos and Belsabel Teklemariam who provided us laptops for setting our project’s python environment should be thanked too for their help. Last but not least, we would like to thank Mai Nefhi College of Engineering and Technology for the Internet access they gave us.

Source: Ministry of Information Eritrea